The mechanically sensitive volume receptors, primarily located in the venoatrial junction area, are essential for blood volume homeostasis. However, the molecular basis of the volume receptors is still unknown.
lood volume is regulated in a complicated system involving many neuronal and endocrine controls to maintain physiological homeostasis. 1 Volume receptors are essential in the detection of blood volume changes 2, 3 and are mainly located in the venoatrial junction and atrium; they detect alterations in central venous pressure and are thus named low-pressure baroreceptors. 4 An increase in central venous pressure stretches the low-pressure baroreceptors and induces the release of atrial natriuretic peptide (ANP) from atrial myocytes. Stretch-activated receptors are also found in the aortic arch and carotid sinus (aortic and carotid baroreceptors), where the volume expansion triggers an autonomic response. 5 As well, renal baroreceptors are involved in blood volume control by increasing the plasma ANP concentration, 5 which induces natriuresis and diuresis in the kidney to return blood volume and pressure back to normal. 1 Although ANP is released in response to volume receptor stretch, the mechano-sensing molecules underlying the mechanotransduction are largely unknown.
Editorial p 781
Previous studies have shown that members of the degenerin/epithelial sodium channel/acid-sensing ion channel (ASIC) family play important roles in neural cardiovascular mechanosensation. 6 Recent studies further demonstrated ASIC2 as an important determinant of arterial baroreceptor sensitivity. 7 Besides ASIC2, other members of the ASIC subfamily are possible candidates contributing to neurosensory mechanotransduction and baroreceptor sensitivity. 8 For example, ASIC3 often colocalizes with ASIC2 in sensory neurons, especially in the aortic baroreceptor nerve terminals. 7 ASIC3 is predominately expressed in peripheral sensory neurons, including those in the nodose ganglia and dorsal root ganglia (DRG). 9-11 Although the major role of ASIC3 is nociception and metaboreception, 8,12-14 mice lacking Asic3 show altered neurosensory mechanotransduction in the inner ear, skin, and gastrointestinal tract. 15-18 A previous report also demonstrated that single nucleotide polymorphism of the Asic3 gene is associated with blood pressure 875 ASIC3 and Blood Volume Expansion regulation in humans. 19 In addition, gadolinium, 20,21 a channel blocker for stretch-activated responses in the atrium, neurons, and carotid baroreceptors, inhibits the acid-induced response in ASIC3 homomeric and ASIC2a+3 heteromeric channels. 22 However, whether ASIC3 is involved in blood volume control is unknown.
We hypothesized that ASIC3 might be expressed in the volume receptors of primary sensory neurons to detect transmural mechanical changes with blood volume expansion (BVE). We thus compared the effect of gadolinium on BVEinduced urine flow and neuronal responses in Asic3 -/-and Asic3 +/+ mice.
Methods

Animals
The investigation conformed to the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH publication No. 85-12, revised 1996), and project approval was granted by the Institute of Animal Care and Use Committee of Academia Sinica. Female Asic3 +/+ (n=92) and Asic3 -/-mice (n=85; both 8-12 weeks old) were littermates from Asic3 +/-mice bred in a CD1 background as previously described. 14, 17 Four Asic3 +/+ mice were used for neural tracing. For urine flow measurements, Asic3 +/+ mice were divided into 3 groups for treatment: without BVE (n=5), with BVE (n=12), and pretreatment with GdCl3, then BVE (n=13). Asic3 -/-mice were divided into 2 groups for treatment: BVE (n=20) and pretreatment with GdCl3 then BVE (n=14). For investigation of BVE-induced phosphorylated extracellular signal-regulated kinase (pERK) immunoreactivity in sensory neurons, Asic3 +/+ mice were divided into 2 groups for treatment: BVE or not (n=6 each). For investigation of colocalization of ASIC3 immunoreactivity and BVE-induced pERK in sensory neurons, both Asic3 +/+ and Asic3 -/-mice were divided into 4 groups for treatment: without BVE (basal), with BVE, basal with GdCl3 pretreatment, and pretreatment with GdCl3 then BVE (n=6 each). For investigation of circulating ANP levels, mice were divided into 4 groups for treatment: without BVE (n=5, both genotypes), with BVE (Asic3 +/+ , n=6; Asic3 -/-, n=10), GdCl3 pretreatment only (n=6, both genotypes), pretreatment with GdCl3 then BVE (Asic3 +/+ , n=5; Asic3 -/-, n=6). Animals were kept in a temperature-controlled environment with a 12-h light/dark cycle from 8:00 to 20:00 hours.
Postmortem Retrograde Tracing for Volume Receptor Cell Bodies
Asic3 +/+ mice (n=2) were killed by overdose of urethane (13 g/kg, intraperitoneally) then perfused with 50 ml normal saline followed by 50 ml 4% paraformaldehyde. The right atrium was opened by cutting the coronary sulcus. A small amount of DiI crystal (Molecular Probes, Eugene, OR, USA) was applied to the venoatrial junction area, then covered with 1% agarose. Mouse bodies were kept in 4% paraformaldehyde solution in the dark and incubated at 37°C. After 14 weeks, the nodose ganglia were dissected and dehydrated in 30% sucrose for 1 day and embedded in tissue-freezing medium to create frozen sections. Nodose ganglia sections, 12-μm thick, were cut every other 36 μm for ASIC3 immunostaining. The specificity of ASIC3 immunoreactivity was validated on Asic3 -/-nodose ganglia, with ASIC3 antibodies showing no staining.
Volume Receptor Nerve Terminals
Nerve terminals in the venoatrial junction were examined by confocal microscopy. Asic3 +/+ mice (n=2) were anaesthetized with pentobarbital (50 mg/kg, intraperitoneally) then perfused with 50 ml normal saline followed by 50 ml of 4% paraformaldehyde. Tissues containing the venoatrial junction and surrounding area, including the right atrium, auricle, superior vena cava, inferior vena cava, and left precaval vein, were dissected. The tissues were immunostained with antibodies against ASIC3 (dilution 1:50, Neuromics, Northfield, MN, USA) and calcitonin gene-related peptide (CGRP; dilution 1:500, Millipore, Billerica, MA, USA) in a free-floating method and visualized with Alexa Flour-conjugated secondary antibodies. Immunofluorescent images were acquired with an Ultra View ERS rapid confocal imager (Perkin Elmer, Wellesley, MA, USA) and merged in 255 serial optical sections (0.2-μm thick in Z-axis).
Blood Volume Expansion
Acute BVE was as described with modification. 23 Mice were anesthetized with urethane (1.3 g/kg body weight, intraperitoneally), received a tracheostomy to minimize airway resistance, and were covered with a warm pad to maintain body temperature. The jugular vein was cannulated with a polyethylene tube (PE-10 tubing) for intravenous injection. The bladder was catheterized with PE-20 tubing for urine collection every 15 min in a preweighed microcentrifuge tube. After surgery, mice were intravenously injected with isotonic normal saline (containing 2% bovine serum albumin [BSA] ) at 120 μl/h for 30 min by microinjection pump. Basal urine output was established by intravenous basal infusion of isotonic-isoncotic normal saline (containing 4.5% BSA) at 4.3 μl · h -1 · g -1 body weight for 1 h. For GdCl3-pretreated groups, 2 mmol/L GdCl3 was included in the isotonic-isoncotic normal saline in the last 30 min of the 1-h basal infusion. Next, mice received a 15-min bolus injection of isotonic-isoncotic normal saline containing urethane (57 mg/kg body weight to maintain anesthesia) at an infusion rate of 114 μl · h -1 · g -1 body weight. To avoid the given anesthetic being diluted and flushed out by the large volume of infused saline, a small amount of urethane was included in the isotonic-isoncotic saline to maintain sufficient anesthesia throughout the experiment. After the bolus injection, the infusion rate was kept at 4.3 μl · h -1 · g -1 body weight with isotonic-isoncotic normal saline for another 105 min.
Immunohistochemistry
ERK phosphorylation is commonly used to assess cellular response to external mechanical stimulation and to indicate the immediate activation of primary sensory neurons. 24, 25 Therefore, we used the pERK response to gauge BVE-evoked neural activation of the DRG and nodose ganglia. Anesthetized mice received an intravenous bolus injection of the isotonic-isoncotic normal saline for 3 min and immediate perfusion with 4% paraformaldehyde. Nodose ganglia and DRG were collected and post-fixed, then dehydrated with 30% sucrose for 1 day and embedded in tissue-freezing medium for frozen sections. The identity of each DRG was judged by the position of the last rib, with T13 ganglia located just below. 26 Sections 12-μm thick were cut every other 60 μm, then incubated with blocking solution (50 mmol/L TRISbuffered saline containing 1% BSA, 0.1% Triton X-100 and 0.02% sodium azide) for 2 h. Primary antibodies against pERK (dilution 1:200, Cell Signalling, Boston, MA, USA) and ASIC3 (dilution 1:50, Neuromics, Northfield, MN, USA) LEE CH et al.
were diluted in blocking solution. The secondary antibodies were Alexa Fluor 594(ab')2 fragments of goat anti-rabbit and Alexa Fluor 488(ab')2 fragments of goat anti-guinea pig (1:200 in blocking solution, Molecular Probes).
Plasma ANP
Plasma ANP concentrations were determined by ANP immunoassay kit (SPI-BIO, Montigny Le Bretonneux, France) according to the manufacturer's instruction. The blood samples were collected at 30 min after the bolus injection by the submandibular method in anesthetized mice and mixed with a 1/10 volume of 0.11 mol/L sodium citrate. The ANP concentration was then converted to the total amount of plasma ANP on the basis of the total plasma volume at 105 min, which was estimated by the following equation: body weight × 1/13 × 0.54 + total input volume (0-105 min) -total urine flow (0-105 min). The total ANP amount at 105 min was equal to the plasma volume at 105 min × plasma ANP concentration. The ratio of the amount of ANP was normalized to the average amount of ANP of the Asic3 +/+ basal group.
Statistical Analysis
Results are presented as mean ± standard error of the mean and analyzed by STATVIEW 5.0 program (SAS Institute, Cary, NC, USA). Two-way ANOVA was used to analyze the data between groups for BVE-induced urine flow, the ratios of pERK immunoreactive neurons to total counted neurons in each ganglion, ratios of pERK-responsive neurons in ASIC3-expressing neurons in selected sensory ganglia of Asic3 +/+ mice, and the ratios of the plasma ANP amount to the Asic3 +/+ baseline and the BVE-induced pERK response in nodose ganglia; analyses were followed by pairwise Tukey test when appropriate. The ratios of pERK-immunoreactive neurons in total ganglia and the colocalization of ASIC3 and pERK were analyzed by one-way ANOVA. In some cases, KruskalWallis one-way ANOVA on Ranks was chosen when normality test or equality test failed in the one-way ANOVA. Correlations of BVE-induced urine flow, pERK response in 
Results
Expression of ASIC3 in Nodose Ganglia and Volume Receptor Nerve Terminals
We first examined whether ASIC3 is expressed in neurons innervating the venoatrial junction (Figure 1 ). We applied DiI crystal to the venoatrial junction area so that the dye would diffuse into volume receptor nerve terminals and then diffuse through the neurons to their cell bodies in the nodose ganglia ( Figures 1A,B) . Retrograde tracing results showed that ASIC3 was expressed in nodose neurons innervating the venoatrial junction area (Figures 1D-F) . To trace the volume receptor nerve terminals, we examined ASIC3 immunoreactivity in the area of the venoatrial junction ( Figure 1C) . The expression of ASIC3 was co-localized with calcitonin gene-related peptide in afferent nerve terminals in the venoatrial junction area (Figures 1G-I) .
BVE Increased Urine Flow Controlled by ASIC3- and GdCl3-Dependent Pathways
To determine the role of ASIC3 in blood volume control, we compared BVE-induced urine flow between Asic3 +/+ and Asic3 -/-mice. As compared with Asic3 +/+ mice without a bolus injection of isotonic-isoncotic saline, Asic3 +/+ mice with a bolus injection showed increased urine flow (Figure 2A) . The same bolus volume infusion also increased urine flow in Asic3 -/-mice, but the amount of urine flow was substantially less than that in Asic3 +/+ mice. Because BVE activates stretchactivated channels on volume receptors, we examined whether the common stretch-activated channel blocker, gadolinium, could inhibit the BVE-induced urine flow in mice. The basal urine flow did not differ between genotypes with 30 min of GdCl3 pretreatment (Figure 2B) . GdCl3 pretreatment signifi- Gadolinium (GdCl3) pretreatment given between 30 and 60 min, and bolus injection given between 60 and 75 min. Asic3 +/+ -BVE, n=12; Asic3 -/--BVE, n=20; Asic3 +/+ -GdBVE, n=13; Asic3 -/--GdBVE, n=14; Asic3 +/+ -basal, n=5. BVE, blood volume expansion, GdBVE, GdCl3 pre-treatment before BVE. (B) Baseline urine flow from 30 to 60 min. Two-way ANOVA revealed no significant difference between groups. (C) Post-BVE urine flow from 75 to 105 min. Two-way ANOVA revealed significant effects of genotype (F(1,55)=16.21, P<0.001) and GdCl3 (F(1,55)=15.718, P<0.001), and no interaction (F(1,55)=1.14, P=0.29). ***P<0.001. NS, not significant; ASIC3, acid-sensing ion channel 3; GT, genotype; Gd, GdCl3 pre-treatment; GT × Gd, genotype × GdCl3 interaction.
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cantly reduced the BVE-induced urine flow in both Asic3 +/+ and Asic3 -/-mice ( Figure 2C) . Two-way ANOVA showed significant effects of genotype (F(1,55)=16.21, P<0.001) and GdCl3 pretreatment (F(1,55)=15.718, P<0.001) but no interaction (F(1,55)=1.14, P=0.29). Although both Asic3 deletion and GdCl3 pretreatment can inhibit BVE-induced urine flow, ASIC3-mediated BVE-induced urine flow may be independent of GdCl3 inhibition.
BVE Induced Transient pERK Immunoreactivity in Primary Afferent Neurons
Because ASIC3 is mainly expressed in primary sensory neurons, we next probed which afferent neurons were sensitive to BVE. To monitor the neural activation response to BVE, we examined pERK immunoreactivity in neurons of the nodose ganglia and DRG from the C4 to L3 level. The number of nodose neurons with pERK immunoreactivity was increased after 3 min of BVE but returned to the baseline level after 5 min of BVE ( Figure 3A) . After 3 min of BVE, only the nodose ganglia and DRG of the C8-T4 and T9-T13 segments showed an increased number of pERK-positive neurons ( Figure 3B ). From this transient pERK immunoreactivity we concluded that neurons of these specific ganglia were sensitive to BVE. 
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ASIC3- and GdCl3-Dependent pERK Responses to BVE
Both the heart and kidney are known to be involved in volume control. Thus, we next analyzed the effect of Asic3 deletion and GdCl3 pretreatment on BVE-induced pERK responses in the nodose ganglia and DRG of C8-T3 (containing neurons innervating the heart) and T12-T13 (containing neurons innervating the kidney), as well as L3 DRG for a negative control. Without GdCl3 pretreatment, two-way ANOVA showed a significant BVE effect in nodose ganglia Pairwise Tukey test revealed a significant difference in BVEinduced pERK immunoreactive neurons between Asic3 -/-and Asic3 +/+ mice only in the nodose ganglia (P<0.001) and DRG of C8 (P<0.007) and T2 (P<0.005), which indicates ASIC3-dependent control in these 3 ganglia types ( Figure 4A) . Asic3 +/+ and Asic3 -/-mice did not differ in the BVE-induced increase of pERK-positive neurons in DRG of T1, T3, T12, and T13, which indicates no ASIC3-dependent control in those 4 ganglia. In Asic3 -/-mice, BVE significantly increased the number of neurons with pERK immunoreactivity in the nodose ganglia and DRG of T1, T3, T12, and T13, which indicates the existence of ASIC3-independent neural control ( Figure 4A ). As expected, BVE did not increase the number of neurons with pERK immunoreactivity in L3 DRG in either genotype. Pretreatment with GdCl3 significantly reduced the number Asic3 +/+ -BVE, n=6. Asic3 +/+ -BVE/Gd, n=5. Asic3 -/--BVE, n=10. Asic3 -/--BVE/Gd, n=6. (C) Ratios of BVE-induced pERK-immunoeactive neurons to total counted neurons in nodose ganglia (n=6 in each group). *P<0.05, **P<0.01, ***P<0.001, two-way ANOVA. ANP, atrial natriuretic peptide; ASIC3, acid-sensing ion channel 3; BVE, blood volume expansion; GT, genotype; Gd, GdCl3; GTxGd, genotype x GdCl3 interaction; pERK, phosphorylated extracellular signal-related kinase. ASIC3 and Blood Volume Expansion of pERK-positive neurons after BVE in all ganglia tested, except L3 DRG, which indicates GdCl3-dependent inhibition in these neurons. Two-way ANOVA revealed a significant BVE effect in the nodose ganglia (F(1,20) (Figure 4B) . Thus, BVE significantly increased the pERKpositive neurons in the nodose ganglia and DRG of T1, T3, T12, and T13 segments in mice pretreated with GdCl3, which indicates GdCl3-independent control in those 5 ganglia types. However, we found a significant genotype × BVE interaction only in nodose ganglia (F(1,20) =4.479, P=0.047). Pairwise Tukey test revealed a significant increase in BVE-induced pERK response in Asic3 +/+ (P=0.003) but not Asic3 -/-(P=0.637) nodose ganglia, which indicates the existence of ASIC3-dependent control under GdCl3 pretreatment conditions. Together, these results indicate that the Asic3 mutation affects the BVE-induced pERK response in a GdCl3-independent manner only in nodose ganglia. Table summarizes the ASIC3-and GdCl3-dependent and -independent controls for the BVE-induced pERK responses in all tested ganglia.
Involvement of ASIC3 in GdCl3-Independent BVE-Induced pERK Response
We next examined whether ASIC3 was expressed in the neurons that were responsible for the GdCl3-independent control of ERK phosphorylation in nodose ganglia. In the examined ganglia, BVE-induced pERK immunoreactivity colocalized with ASIC3 in a substantial number of neurons ( Figure 5A ). The colocalization of ASIC3/pERK represented ~60% of total pERK immunoreactive neurons in nodose ganglia ( Figure 5B) . With GdCl3 pretreatment, the ratio of BVE-induced ASIC3 to pERK colocalization in nodose ganglia was reduced to ~40% of total pERK, but still significantly higher than the basal level ( Figure 5C ). We further used two-way ANOVA to analyze the effect of BVE and GdCl3 pretreatment on the pERK response in the total ASIC3-positive neurons ( Figure 5D ). The result showed significant effects of BVE (F(1,20)=61.234, P<0.001) and GdCl3 (F(1,20)=169.409, P<0.001) and a significant interaction (F(1,20)=71.118, P<0.001). Thus, GdCl3 pretreatment significantly inhibited BVE-induced pERK responses in ASIC3-expressing neurons. However, pairwise Tukey test showed a significant increase in the BVE-induced pERK response as compared with baseline in ASIC3-expressing nodose neurons, even with GdCl3 pretreatment (basalGd vs. BVEGd, P=0.004), which suggests that these neurons contributed to the GdCl3-independent control of blood volume.
BVE Increased Plasma ANP Level
To further investigate how ASIC3 activation is involved in the regulation of BVE-induced urine flow, we examined circulating ANP levels. Both Asic3 knockout and GdCl3 pretreatment did not affect the baseline ANP level ( Figure 6A ). In contrast, BVE caused an increase in circulating ANP level in Asic3 +/+ mice, which could be attenuated by Asic3 knockout or GdCl3 pretreatment ( Figure 6B ). 
Discussion
Acute BVE approaches have been used to investigate the molecular mechanism of volume homeostasis and reveal the involvement of the ANP-guanylyl cyclase-A receptor system in response to volume expansion. 23, 27 We used the BVE approach to reveal the molecular and neuronal specificity of the volume receptor. We found that ASIC3 was involved in blood volume control, and that Asic3-deleted mice showed a reduced BVE-induced urine flow, pERK response in specific visceral afferent neurons, and circulating ANP level. We also revealed how ASIC3 contributed to the neuronal control of blood volume through a GdCl3-independent pathway. In mice pretreated with GdCl3, BVE could still increase urine flow, so we suggest a GdCl3-independent pathway in the control of blood volume homeostasis. The GdCl3-independent blood volume control might involve an ASIC3-dependent pathway, because Asic3 deletion and GdCl3 pretreatment had a synergic effect on the inhibition of BVE-induced urine flow. In the pERK experiments, the GdCl3-independent pathway contained ASIC3-expressing neurons in nodose ganglia ( Figure 5) . Moreover, Asic3 knockout reduced the BVE-induced plasma ANP elevation via a GdCl3-independent pathway. Nodose ASIC3-expressing afferents innervate the venoatrial junction, which contains very little ANP. Therefore, BVE might activate ASIC3 nerve terminals to elicit a signal for ANP release, which is relayed across the atrial tissues to the peptide stores in atrial myocytes. 4 GdCl3 is a common inhibitor of stretch-activated ion channels in many cell types. 20 GdCl3 at 20-80 μmol/L is enough to block stretch-activated ANP secretion in isolated rat atria. 21 However, the effect of GdCl3 in blood volume con- trol in vivo has not been tested. Here we showed that GdCl3 effectively inhibits BVE-induced plasma ANP elevation in an ASIC3-independent manner in vivo. GdCl3 might act on stretch-activated ion channels expressed on the surface of sensory neurons, because it can largely block the BVEinduced pERK response in visceral afferent neurons. Interestingly, GdCl3 also inhibited BVE-induced pERK responses in ASIC3-expressing neurons. Nevertheless, the expression of ASIC3 is not necessary for pERK responses. Although GdCl3 is an effective blocker of acid-induced currents mediated by ASIC3 and ASIC2a+3 channels with an IC50 of ~40 μmol/L, 22 there is no evidence that GdCl3 can block stretch-activated currents mediated through ASIC3. Whether other channels are responsible for the pERK responses in these neurons is an unknown, but intriguing possibility. We are far from determining the exact identity of GdCl3-dependent stretch-activated ion channels sensing volume expansion, and we especially cannot exclude the contribution of ASIC2, which is required for arterial baroreceptor activity. 7 The other candidate might be TRPV1, which plays a role in neurosensory mechanotransduction involved in cardiovascular homeostasis. 2,28, 29 Although our data support a role for ASIC3 in blood volume control, obtaining direct evidence of the involvement of ASIC3 in sensing the volume receptor stretch is still a challenge. Previous studies have demonstrated that loss of Asic3 in mice alters mechanotransduction in the gastrointestinal tract, skin, and auditory system. 15-18 However, approaches involving direct indentation on neuron soma have failed to support a role of ASIC3 for mechanotransduction in isolated neurite-free DRG neurons. 30 Because neurites of visceral afferent neurons are the anatomical sites for stretch-activated ion channels in volume receptors, previous research may have missed the subtle change in mechanically activated currents in the DRG of Asic3 -/-mice. Because investigating stretch neurites on isolated DRG neurons is technically difficult, most of the previous studies of neurosensory mechanotransduction have involved neurite-free DRG neurons. [30] [31] [32] Recent advances in neurosensory mechanotransduction have been successful in developing a method of stretching neurites via an indentation on surface-modified elastic matrices. 33, 34 This approach has conquered the hurdle of neurite stretching and might enable probing of the role of ASIC3 and/or other ASIC subtypes in volume receptor stretching.
Finally, our pERK results provide a comprehensive picture of the distribution of volume-sensitive neurons, which are located in the nodose ganglia and DRG of C8-T4 and T9-T13. This information on these volume-sensitive ganglia concurs with current knowledge of volume receptors distributed in cardiac and renal afferents. 5 Moreover, organs involved in body fluid homeostasis, such as lung, liver and colon, are also innervated by sensory neurons derived from these volume-sensitive ganglia. Further research into the innervation of these volume-sensitive neurons will expand our understanding of volume receptors.
In conclusion, our results support the involvement of ASIC3 in sensing alterations in blood volume.
